HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Raises Price Target to $28

HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $25 to $28.